David Cox, MD
Infectious Disease · Greenwood, INNPI 1861474231
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,340 of the $1,593 with a category attached, or 84.1%. It is spread thinly across 20 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations.
Across 95 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$281
- AbbVie$179
- Gilead$148
- Shionogi Inc$146
- Paratek Pharmaceuticals, Inc.$139
- Insmed, Inc.$138
- plus $562 from 14 others
What the payments were for
- Food & beverage$1,34084%
- Education$25416%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 22 | $281 |
| AbbVie(2 entities) | 13 | $179 |
| Gilead | 9 | $148 |
| Shionogi Inc | 8 | $146 |
| Paratek Pharmaceuticals, Inc. | 9 | $139 |
| Insmed, Inc. | 6 | $138 |
| Astellas Pharma US Inc | 5 | $123 |
| Viiv Healthcare Company | 7 | $96 |
| Janssen Products, LP | 1 | $60 |
| Napo Pharmaceuticals Inc | 2 | $47 |
| Amgen | 2 | $44 |
| Johnson & Johnson | 3 | $37 |
| Cormedix Inc. | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| Dynavax Technologies Corporation | 1 | $18 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $16 |
| Bio Products Laboratory USA, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| La Jolla Pharmaceutical Company | 1 | $11 |
How this compares
$1,593 in reported general payments places this provider in the 75th percentile of 152 infectious disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 40 | $155,847 |
| Daptomycin | 16 | $61,241 |
| IsentressRaltegravir Potassium | 24 | $47,813 |
| DovatoDolutegravir Sodium/Lamivudine | 12 | $40,725 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 35 | $37,248 |
| Lopinavir-RitonavirLopinavir/Ritonavir | 16 | $17,062 |
| Rifampin | 67 | $5,662 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 25 | $5,204 |
| Ethambutol Hcl | 55 | $4,640 |
| CeftriaxoneCeftriaxone Sodium | 23 | $2,346 |
| Cephalexin | 104 | $1,843 |
| Doxycycline Hyclate | 38 | $1,561 |
| Azithromycin | 62 | $1,304 |
| Vancomycin Hcl | 13 | $1,165 |
| Minocycline Hcl | 13 | $860 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadGenvoya | $148 | $155,84740 claims |
| MerckIsentress | $281 | $47,81324 claims |
| Viiv Healthcare CompanyDovato | $96 | $40,72512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 152 infectious disease providers in Indiana.
Other infectious disease in Greenwood
- Aliya HaiderGreenwood$3K
- Mona DesaiGreenwood$2K
- Timothy FransonZionsville$303K
- Donald TherasseZionsville$75K
- Anwer JaffriTerre Haute$63K
- Jason BaileyFort Wayne$60K
- Markian BochanCarmel$54K
- Samir GuptaIndianapolis$53K
- Erica Kaufman WestDyer$48K
- Tracey IkerdCarmel$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.